Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction

作者：Gutstein D E^*; Krishna R; Johns D; Surks H K; Dansky H M; Shah S; Mitchel Y B; Arena J; Wagner J A

来源：Clinical Pharmacology & Therapeutics, 2012, 91(1): 109-122.

DOI：10.1038/clpt.2011.271

Cholesteryl ester transfer protein (CETP) inhibition is a promising experimental strategy to raise high-density lipoprotein cholesterol (HDL-C) and reduce cardiovascular risk. This review focuses on the highly selective and potent CETP inhibitor anacetrapib and discusses the available preclinical and clinical information pertaining to it. We also describe strategies to target HDL-C, discuss the mechanism underlying CETP inhibition and its effects on lipid biology, and give an overview of other CETP inhibitors that are currently in development.

• 出版日期2012-1